Cellectar Biosciences, Inc. CLRB

Will bounce back , strong data

Cellectar Biosciences (CLRB)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Cellectar Biosciences, with a price target of $7.00. The company’s shares closed last Tuesday at $3.61.

According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.2% and a 29.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.

Check also VANI lots insider are buying 1.070$

Anybody hear about earnings?

15%+15%+5% drop. It dropped 35% in 3 days! When stop bleeding!

Market is red because of coronavirus. This stock drops too. Not sure when is the good news!!!

Another 15% drop today! No catalyst for this stock! People are running away!

15% drop after clinical data disclosed. What else we expect next? Offering!